Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 6:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 123 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: autologous dendritic cell cancer vaccine Clear all
Not listed Phase 2 Interventional

Ovarian Dendritic Cell Vaccine Trial

NCT00703105
View directory record Official record
Conditions
Ovarian Cancer
Interventions
DC vaccination
Biological
Lead sponsor
Loyola University
Other
Eligibility
18 Years and older · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2021
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 26, 2021 · Synced Oct 13, 2026, 6:34 AM EDT
Completed Phase 2 Interventional

Vaccine Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer

NCT00019929
View directory record Official record
Conditions
Lung Cancer
Interventions
mutant p53 peptide pulsed dendritic cell vaccine, adjuvant therapy
Biological · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
2
States / cities
Bethesda, Maryland • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Oct 13, 2026, 6:34 AM EDT
Completed Phase 2 Interventional Results available

Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Patients With Locally Recurrent or Metastatic Breast Cancer

NCT00266110
View directory record Official record
Conditions
Breast Cancer
Interventions
sargramostim, therapeutic autologous dendritic cells, trastuzumab, vinorelbine ditartrate
Biological · Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 12, 2018 · Synced Oct 13, 2026, 6:34 AM EDT
Completed Phase 2 Interventional

A Pilot Study of Tumor Cell Vaccine for High-risk Solid Tumor Patients Following Stem Cell Transplantation

NCT00405327
View directory record Official record
Conditions
Sarcoma, Neuroblastoma, Wilm's Tumor
Interventions
Tumor lysate-pulsed dendritic cell (DC) vaccine, Hematopoietic stem cell transplantation (HSCT)
Biological · Other
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
Up to 30 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 13, 2026, 6:34 AM EDT
Terminated Phase 1 Interventional

Vaccine Therapy in Treating Patients Who Are Undergoing Surgery for Stage IB, Stage II, or Stage IIIA Non-Small Cell Lung Cancer

NCT00098917
View directory record Official record
Conditions
Lung Cancer
Interventions
autologous tumor cell vaccine, therapeutic autologous dendritic cells, adjuvant therapy, biological therapy, conventional surgery, surgery, tumor cell derivative vaccine, vaccine therapy
Drug · Procedure
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 28, 2008 · Synced Oct 13, 2026, 6:34 AM EDT
Terminated Phase 1 Interventional

Local Modulation of Immune Receptors to Enhance the Response to Dendritic Cell Vaccination in Metastatic Melanoma

NCT01216436
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Vaccination with RNA-transfected mature autologous DC
Biological
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 25, 2015 · Synced Oct 13, 2026, 6:34 AM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

NCT00639639
View directory record Official record
Conditions
Malignant Neoplasms of Brain
Interventions
tetanus toxoid, therapeutic autologous dendritic cells, therapeutic autologous lymphocytes
Biological
Lead sponsor
Gary Archer Ph.D.
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2022
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 13, 2023 · Synced Oct 13, 2026, 6:34 AM EDT
Completed Phase 1 Interventional

Immune Responses to Autologous Langerhans-type Dendritic Cells Electroporated With mRNA Encoding a Tumor-associated Antigen in Patients With Malignancy: A Single-arm Phase I Trial in Melanoma

NCT01456104
View directory record Official record
Conditions
Melanoma
Interventions
Langerhans-type dendritic cells (a.k.a. Langerhans cells or LCs)
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 13, 2023 · Synced Oct 13, 2026, 6:34 AM EDT
Completed Phase 1Phase 2 Interventional

Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer

NCT00004211
View directory record Official record
Conditions
Prostate Cancer
Interventions
PSA RNA-pulsed dendritic cell vaccine
Biological
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Male only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 21, 2013 · Synced Oct 13, 2026, 6:34 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Dendritic Cell Vaccine Study (DC/PC3) for Prostate Cancer

NCT00345293
View directory record Official record
Conditions
Prostate Cancer
Interventions
autologous dendritic cell vaccine (DC/PC3)
Biological
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years and older · Male only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 18, 2016 · Synced Oct 13, 2026, 6:34 AM EDT
Completed Phase 1 Interventional

Autologous Dendritic Cells Pulsed With Autologous Apoptotic Tumor Cells Administered to Patients With Brain Tumors

NCT00893945
View directory record Official record
Conditions
Brain Tumors
Interventions
DC/AAT, DC/AAT-Flu, DC/KLH
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 23, 2014 · Synced Oct 13, 2026, 6:34 AM EDT
Terminated Phase 1 Interventional

RENEW: Feasibility of CMV RNA-Pulsed Dendritic Cells Vaccines for the Treatment of Newly Diagnosed Glioblastoma Patients.

NCT04963413
View directory record Official record
Conditions
Glioblastoma
Interventions
Autologous DCs derived from PBMC loaded with RNA encoding the human CMV matrix protein pp65-flLAMP plus GM-CSF
Biological
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 90 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Oct 13, 2026, 6:34 AM EDT
Recruiting Phase 1Phase 2 Interventional

Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer

NCT03942328
View directory record Official record
Conditions
Stage III Hepatocellular Carcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Unresectable Hepatocellular Carcinoma, Unresectable Intrahepatic Cholangiocarcinoma
Interventions
Atezolizumab, Bevacizumab, External Beam Radiation Therapy, Pheresis, Pneumococcal 13-valent Conjugate Vaccine, Therapeutic Autologous Dendritic Cells, Durvalumab, Esophagogastroduodenoscopy, Computed Tomography, Positron Emission Tomography, Magnetic Resonance Imaging, Biopsy Procedure, Biospecimen Collection
Biological · Radiation · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 13, 2026, 6:34 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma

NCT00923351
View directory record Official record
Conditions
Neuroblastoma, Sarcoma, Rhabdomyosarcoma-Embryonal, Rhabdomyosarcoma- Alveolar, Neuroectodermal Tumors, Primitive, Peripheral
Interventions
Tumor Purged/CD25 Depleted Lymphocytes, Tumor Purged/CD25 Depleted Lymphocytes with Tumor Lysate/KLH Pulsed Dendritic Cell Vaccine, rhIL-7, Tumor Lysate/KLH Pulsed Dendritic Cell Vaccine
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
19 Months to 35 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 15, 2018 · Synced Oct 13, 2026, 6:34 AM EDT
Completed Phase 1 Interventional

Biological Therapy in Treating Patients With Metastatic Cancer

NCT00004604
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Gastric Cancer, Head and Neck Cancer, Liver Cancer, Lung Cancer, Metastatic Cancer, Ovarian Cancer, Pancreatic Cancer, Testicular Germ Cell Tumor
Interventions
CEA RNA-pulsed DC cancer vaccine
Biological
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2002
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 22, 2013 · Synced Oct 13, 2026, 6:34 AM EDT
Completed Phase 2 Interventional

Dendritic Cell Vaccine for Patients With Brain Tumors

NCT01204684
View directory record Official record
Conditions
Glioma, Anaplastic Astrocytoma, Anaplastic Astro-oligodendroglioma, Glioblastoma
Interventions
autologous tumor lysate-pulsed DC vaccination, Tumor lysate-pulsed DC vaccination+0.2% resiquimod, Tumor-lysate pulsed DC vaccination +adjuvant polyICLC
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 28, 2024 · Synced Oct 13, 2026, 6:34 AM EDT
Completed Phase 1Phase 2 Interventional

RNA-Loaded Dendritic Cell Cancer Vaccine

NCT00087984
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
MB-002
Biological
Lead sponsor
Argos Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
3
States / cities
Orange, California • Buffalo, New York • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 18, 2013 · Synced Oct 13, 2026, 6:34 AM EDT
Completed Phase 1Phase 2 Interventional

Chemotherapy Followed By Vaccine Therapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer

NCT00049218
View directory record Official record
Conditions
Lung Cancer
Interventions
Autologous dendritic cell-adenovirus p53 vaccine, Carboplatin, Etoposide
Biological · Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2014
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 9, 2014 · Synced Oct 13, 2026, 6:34 AM EDT
Terminated Phase 1 Interventional

Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer

NCT00010127
View directory record Official record
Conditions
Prostate Cancer
Interventions
therapeutic autologous dendritic cells
Biological
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 21, 2013 · Synced Oct 13, 2026, 6:34 AM EDT
Completed Phase 2 Interventional Results available

Paclitaxel, Cyclophosphamide & Doxorubicin, Autologous Dendritic Cells & Surgery in Stage II/III Breast Cancer (Women)

NCT00499083
View directory record Official record
Conditions
Breast Cancer
Interventions
therapeutic autologous dendritic cells, aromatase inhibition therapy, cyclophosphamide, doxorubicin hydrochloride, paclitaxel, tamoxifen citrate, gene expression analysis, protein expression analysis, reverse transcriptase-polymerase chain reaction, immunoenzyme technique, immunohistochemistry staining method, laboratory biomarker analysis, adjuvant therapy, biopsy, conventional surgery, neoadjuvant therapy, radiation therapy
Biological · Drug · Genetic + 3 more
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 120 Years · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
2
States / cities
Tampa, Florida • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 29, 2023 · Synced Oct 13, 2026, 6:34 AM EDT
Terminated Phase 2 Interventional Results available

Dendritic Cells (DC) Vaccine for Metastatic Melanoma

NCT01042366
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Vaccination
Biological
Lead sponsor
John Kirkwood
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 16, 2017 · Synced Oct 13, 2026, 6:34 AM EDT
Active, not recruiting Phase 1 Interventional

CCL21-Gene Modified Dendritic Cell Vaccine and Pembrolizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer

NCT03546361
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Autologous Dendritic Cell-Adenovirus CCL21 Vaccine, Pembrolizumab
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Oct 13, 2026, 6:34 AM EDT
Completed Phase 2 Interventional

Vaccine Therapy in Treating Patients With Unresected Stage III or Stage IV Melanoma

NCT00107159
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
autologous dendritic cell-allogeneic melanoma tumor cell lysate vaccine
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 6, 2013 · Synced Oct 13, 2026, 6:34 AM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients With Advanced or Metastatic Cancer

NCT00027534
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Gallbladder Cancer, Gastric Cancer, Head and Neck Cancer, Liver Cancer, Ovarian Cancer, Pancreatic Cancer, Testicular Germ Cell Tumor
Interventions
TRICOM-CEA(6D)
Biological
Lead sponsor
Michael Morse, MD
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 8, 2014 · Synced Oct 13, 2026, 6:34 AM EDT